Table of Contents Table of Contents
Previous Page  5 / 1020 Next Page
Information
Show Menu
Previous Page 5 / 1020 Next Page
Page Background

ESTRO 35 content

Saturday 30 April 2016

Teaching Lecture

Technology assessment (Abs. 1)

CRISPR/CAS technology: from cells to mice to stem cell therapy (Abs. 2)

Partial Breast Irradiation: who, when and how? (Abs. 3)

New tools to reduce toxicity in pelvic radiation (Abs. 4)

Role of brachytherapy in the management of paediatric tumors (Abs. 5)

Challenges in MR guided radiotherapy (Abs. 6)

Patient specific quality assurance in proton therapy (Abs. 7)

Balancing toxicity and disease control in the evolution of

radiotherapy technology (Abs. 8)

Symposium

Selection of patients for proton therapy (Abs. 9-11)

Mitigating normal tissue toxicity (Abs. 12-14)

Regional nodal irradiation for breast cancer (Abs. 15-17)

Assessment and management of rectal morbidity (Abs. 18-20)

Towards user oriented QA procedures for treatment verification (Abs.

21-23)

Robust and accurate functional MRI for radiotherapy (Abs. 24-26)

Joint Symposium

ESTRO-IAEA: Joint ESTRO-IAEA efforts on dosimetry, QA and audit for

advanced treatment techniques (Abs. 27-29)

Symposium

Strategies for treatment planning (Abs. 30-32)